Home Situations ZEAL.CO — Strong businesses outperforming
Situation · 2026-04-24

ZEAL.CO — Strong businesses outperforming

Confidence Fracture Despite Breakout Growth

Updated 2026-04-16 · Ref: Biotechnology
Key metrics — 2026-04-16
Peer score
84
Quality pct
100
Valuation pct
88
52w drawdown
-42.3%
21d vs sector
+12.1%
Peer group
Biotechnology
Situation summary

Breakout revenue growth (+661% YoY) and a swing to net income signal strong fundamentals, but persistent volatility (66.1%) and a -75.4% drawdown point to a deep confidence fracture. The core business remains robust, with a late-stage pipeline and positive earnings. Current stress is concentrated in market stability and sentiment, not operations. A rerating would require sustained stability and trend improvement, plus regulatory milestones.

Published by AssetNext · 2026-04-13

All companies with this signal today

View full list: Strong businesses outperforming →

Related pages for ZEAL.CO
Full peer analysis for Zealand Pharma A/S →Similar companies to ZEAL.COZEAL.CO peersAll ZEAL.CO comparisonsSTOXX 600 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-04-16 Strong businesses outperforming 84 -42.3% +12.1%
2026-04-10 Strong businesses outperforming 83 -47.3% +18.7%
2026-04-07 Strong businesses under pressure 84 -49.9% -26.5%
2026-04-07 Structural weakness emerging 84 -49.9% -26.5%
2026-03-30 Strong businesses under pressure 84 -48.0% -17.8%
2026-03-30 Structural weakness emerging 84 -48.0% -17.8%

See ZEAL.CO's full peer analysis

Break down ZEAL.CO's structural position across all peer dimensions with the interactive app.

Open ZEAL.CO in AssetNext →